Study of trilaciclib to prevent low blood counts in Ewing's sarcoma chemotherapy
Treatments studied
Part of Cancer clinical trials.
This trial tests whether the drug trilaciclib can reduce low blood cell counts caused by chemotherapy in people with Ewing's sarcoma. If you qualify, you may receive a medication that could help protect your bone marrow during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 40 years old
- You have been diagnosed with Ewing's sarcoma
- You have not had any cancer treatment other than surgery
- Your blood counts, kidney and liver function are good enough
- You are able to use effective birth control if needed
- You have no serious heart problems or other major health issues
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called trilaciclib, given along with standard chemotherapy (etoposide plus cisplatin or carboplatin) and radiation. The goal is to see if trilaciclib can help protect your bone marrow from the side effects of treatment.
This study tests whether adding trilaciclib to a new chemotherapy (sacituzumab tirumotecan) can help people with EGFR-mutant lung cancer that keeps growing after certain targeted treatments. The goal is to see if it slows the cancer and reduces side effects.
This trial tests a new drug combination (trilaciclib plus docetaxel) for people with advanced lung cancer (NSCLC) whose cancer has progressed after at least one prior treatment. The goal is to see if adding trilaciclib helps the chemotherapy work better with fewer side effects.
This trial tests an investigational drug called trilaciclib that is given before chemoradiation to help protect your bone marrow and reduce side effects like low blood counts. It is for people with a specific type of esophageal cancer who have finished their main treatment.
This trial tests whether taking trilaciclib alongside standard chemotherapy can help prevent low blood cell counts (myelosuppression) in people with limited-stage small cell lung cancer. It may help you stay stronger during treatment.
This trial tests if trilaciclib can protect your bone marrow during chemotherapy for advanced non-small cell lung cancer. The goal is to reduce side effects like low blood counts, which can cause fatigue, infections, or bleeding.
Hear when a new Ewing Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.